^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
autologous TRAC locus-inserted CD19-STAR-T
i
Other names: autologous TRAC locus-inserted CD19-STAR-T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chinese PLA General Hospital
Drug class:
CD19 inhibitor
Related drugs:
over1year
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
P1/2, N=38, Recruiting, Chinese PLA General Hospital | Initiation date: Dec 2022 --> Jun 2023
Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
2years
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL (clinicaltrials.gov)
P1/2, N=38, Recruiting, Chinese PLA General Hospital
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
Share via
